Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio Key International (BKYI) Common Equity (2016 - 2025)

Bio Key International's Common Equity history spans 16 years, with the latest figure at $6.0 million for Q3 2025.

  • For Q3 2025, Common Equity rose 4443.74% year-over-year to $6.0 million; the TTM value through Sep 2025 reached $6.0 million, up 4443.74%, while the annual FY2024 figure was $3.8 million, 254.66% up from the prior year.
  • Common Equity for Q3 2025 was $6.0 million at Bio Key International, down from $6.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $19.6 million in Q1 2021 and bottomed at -$1.1 million in Q2 2024.
  • The 5-year median for Common Equity is $6.0 million (2025), against an average of $7.7 million.
  • The largest annual shift saw Common Equity tumbled 184.84% in 2024 before it soared 4443.74% in 2025.
  • A 5-year view of Common Equity shows it stood at $15.6 million in 2021, then tumbled by 66.05% to $5.3 million in 2022, then plummeted by 79.94% to $1.1 million in 2023, then soared by 254.66% to $3.8 million in 2024, then skyrocketed by 60.26% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for BKYI's Common Equity are $6.0 million (Q3 2025), $6.9 million (Q2 2025), and $7.5 million (Q1 2025).